A recent study revealed that the novel class I HDACi HCH9033 synergised with FLT3 inhibitor quizartinib and rescued quizartinib resistance in FLT3 ITD AML via enhancing DNA damage response [170]. This evidence concerns the gene FLT3 and acute myeloid leukemia.